JPRN-jRCT2071210055已完成1 期
Investigation of safety, tolerability and pharmacokinetic properties of multiple doses of oral NNC0385-0434 in healthy, male Japanese participants
Sudoh Yuki0 个研究点目标入组 36 人开始时间: 2021年8月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
The conclusions of this study that investigates the safety, tolerability and pharmacokinetic properties, and explores the pharmacodynamic effects of multiple doses of oral NNC0385-0434 (15, 40 and 100 mg) in healthy, male Japanese participants are: -Multiple once daily oral NNC0385-0434 doses of up to 100 mg were well-tolerated and no safety concerns were identified. -No deviation from dose proportionality was observed in NNC0385-0434 exposure. -Median NNC0385-0434 half-life ranged from 186 to 203 hours
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 22age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- •2. Male, aged 20-55 years (both inclusive) at the time of signing informed consent.
- •3. Both parents of Japanese descent.
- •4. Body weight >=54.0 kg
- •5. Body mass index (BMI) between 20.0 and 34.9 kg/m2 (both inclusive)
- •6. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiograms (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
排除标准
- •Any disorder, which in the investigators opinion might jeopardise participant safety or compliance with the protocol
研究者
相似试验
Unknown
1 期
A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA CapsuleSchizophreniaNCT05233657Zhejiang Jingxin Pharmaceutical Co., Ltd.58
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy AdultsHealthyNCT01050127Abbott36
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly SubjectsHealthyNCT00968422Abbott28
Unknown
1 期
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.Renal AnemiaNCT04775615Jiangsu HengRui Medicine Co., Ltd.36
Unknown
1 期
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.Anemia Associated Chronic Kidney DiseaseNCT04470063Jiangsu HengRui Medicine Co., Ltd.30